Aspirin plus Rivaroxaban versus Rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: the multicenter, multinational, randomized, open-label ARIVA trial
BACKGROUND: In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
28 January 2025
|
| In: |
Circulation
Year: 2025, Volume: 151, Issue: 12, Pages: 835-846 |
| ISSN: | 1524-4539 |
| DOI: | 10.1161/CIRCULATIONAHA.124.073050 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1161/CIRCULATIONAHA.124.073050
|
| Author Notes: | Stefano Barco, MD, Houman Jalaie, MD, Tim Sebastian, MD, Simon Wolf, MMed, Riccardo M. Fumagalli, MD, Michael Lichtenberg, MD, Thomas Zeller, MD, Christian Erbel, MD, Oliver Schlager, MD, and Nils Kucher, MD |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949769887 | ||
| 003 | DE-627 | ||
| 005 | 20260120133900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260120s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.124.073050 |2 doi | |
| 035 | |a (DE-627)1949769887 | ||
| 035 | |a (DE-599)KXP1949769887 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Barco, Stefano |e VerfasserIn |0 (DE-588)1279725958 |0 (DE-627)1832902188 |4 aut | |
| 245 | 1 | 0 | |a Aspirin plus Rivaroxaban versus Rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome |b the multicenter, multinational, randomized, open-label ARIVA trial |c Stefano Barco, MD, Houman Jalaie, MD, Tim Sebastian, MD, Simon Wolf, MMed, Riccardo M. Fumagalli, MD, Michael Lichtenberg, MD, Thomas Zeller, MD, Christian Erbel, MD, Oliver Schlager, MD, and Nils Kucher, MD |
| 264 | 1 | |c 28 January 2025 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.01.2026 | ||
| 520 | |a BACKGROUND: In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial (Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS) tested whether 100 mg of daily aspirin plus 20 mg of rivaroxaban is superior to 20 mg of rivaroxaban alone to prevent stent thrombosis within 6 months after stent placement for post-thrombotic syndrome. - METHODS: In this multinational, academic, open-label, independently adjudicated trial, patients with a Villalta score >4 points and a stenosis or occlusion of the inferior vena cava, iliac veins, or common femoral vein successfully treated with venous stent placement were randomized in a 1:1 fashion to the study groups. Key exclusion criteria included <18 or >75 years of age, contraindications to anticoagulant use, or acute venous thrombosis <3 months. The primary efficacy outcome was the composite of no occlusion in the treated segment assessed at serial duplex ultrasound examinations or no reintervention needed to maintain patency within 6 months. Secondary outcomes, including Villalta score, quality of life, and safety outcomes, were also assessed. The study was registered at ClinicalTrials.gov (NCT04128956). - RESULTS: From 2020 through 2022, 172 patients were screened, 169 were randomized, and 162 were included in the full analysis set, receiving either aspirin plus rivaroxaban (n=80) or rivaroxaban alone (n=82) for 6 months. Mean±SD age was 42.8±14.7 years; 103 patients (60.9%) were women; 154 patients (97.5%) were White; and leg ulcers were present in 7% of patients. The primary patency rate at 6 months was 94.8% versus 92.4% (absolute risk difference, 2.4% [95% CI, -13.6 to 18.0]), respectively. The mean±SD decrease in the Villalta score for the affected leg (without ulcer) from baseline to 6 months was -6.7±4.4 and -7.0±5.2 points (P=0.36), respectively. There were no differences in other outcomes or quality of life at 6 months. No major bleeding occurred. - CONCLUSIONS: The overall primary patency rate during the first 6 months after endovascular intervention for post-thrombotic syndrome was higher than expected and comparable between patients receiving aspirin combined with rivaroxaban and those receiving rivaroxaban alone. - REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04128956. | ||
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a aspirin | |
| 650 | 4 | |a Aspirin | |
| 650 | 4 | |a Drug Therapy, Combination | |
| 650 | 4 | |a endovascular procedures | |
| 650 | 4 | |a Factor Xa Inhibitors | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Platelet Aggregation Inhibitors | |
| 650 | 4 | |a post-thrombotic syndrome | |
| 650 | 4 | |a Postthrombotic Syndrome | |
| 650 | 4 | |a rivaroxaban | |
| 650 | 4 | |a Rivaroxaban | |
| 650 | 4 | |a Stents | |
| 650 | 4 | |a thrombosis | |
| 650 | 4 | |a Treatment Outcome | |
| 650 | 4 | |a Venous Thrombosis | |
| 700 | 1 | |a Jalaie, Houman |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sebastian, Tim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolf, Simon |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fumagalli, Riccardo M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lichtenberg, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zeller, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Erbel, Christian |d 1976- |e VerfasserIn |0 (DE-588)132600927 |0 (DE-627)524413401 |0 (DE-576)299249603 |4 aut | |
| 700 | 1 | |a Schlager, Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kucher, Nils |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950 |g 151(2025), 12 vom: März, Seite 835-846 |h Online-Ressource |w (DE-627)265784670 |w (DE-600)1466401-X |w (DE-576)074891189 |x 1524-4539 |7 nnas |a Aspirin plus Rivaroxaban versus Rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome the multicenter, multinational, randomized, open-label ARIVA trial |
| 773 | 1 | 8 | |g volume:151 |g year:2025 |g number:12 |g month:03 |g pages:835-846 |g extent:12 |a Aspirin plus Rivaroxaban versus Rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome the multicenter, multinational, randomized, open-label ARIVA trial |
| 856 | 4 | 0 | |u https://doi.org/10.1161/CIRCULATIONAHA.124.073050 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260120 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 132600927 |a Erbel, Christian |m 132600927:Erbel, Christian |d 910000 |d 910100 |d 50000 |e 910000PE132600927 |e 910100PE132600927 |e 50000PE132600927 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1949769887 |e 485515962X | ||
| BIB | |a Y | ||
| SER | |a newspaper | ||
| JSO | |a {"person":[{"roleDisplay":"VerfasserIn","family":"Barco","display":"Barco, Stefano","role":"aut","given":"Stefano"},{"family":"Jalaie","roleDisplay":"VerfasserIn","given":"Houman","display":"Jalaie, Houman","role":"aut"},{"role":"aut","display":"Sebastian, Tim","given":"Tim","roleDisplay":"VerfasserIn","family":"Sebastian"},{"family":"Wolf","roleDisplay":"VerfasserIn","given":"Simon","role":"aut","display":"Wolf, Simon"},{"given":"Riccardo M.","role":"aut","display":"Fumagalli, Riccardo M.","roleDisplay":"VerfasserIn","family":"Fumagalli"},{"family":"Lichtenberg","roleDisplay":"VerfasserIn","display":"Lichtenberg, Michael","role":"aut","given":"Michael"},{"display":"Zeller, Thomas","role":"aut","given":"Thomas","family":"Zeller","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Erbel, Christian","given":"Christian","family":"Erbel","roleDisplay":"VerfasserIn"},{"given":"Oliver","display":"Schlager, Oliver","role":"aut","roleDisplay":"VerfasserIn","family":"Schlager"},{"roleDisplay":"VerfasserIn","family":"Kucher","given":"Nils","role":"aut","display":"Kucher, Nils"}],"note":["Gesehen am 20.01.2026"],"physDesc":[{"extent":"12 S."}],"relHost":[{"origin":[{"dateIssuedDisp":"1950-","publisher":"Lippincott, Williams & Wilkins ; Ovid","dateIssuedKey":"1950","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]"}],"id":{"zdb":["1466401-X"],"issn":["1524-4539"],"eki":["265784670"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 10.10.2025"],"part":{"pages":"835-846","text":"151(2025), 12 vom: März, Seite 835-846","year":"2025","issue":"12","volume":"151","extent":"12"},"type":{"media":"Online-Ressource","bibl":"newspaper"},"corporate":[{"display":"American Heart Association","role":"isb","roleDisplay":"Herausgebendes Organ"}],"language":["eng"],"pubHistory":["1.1950 -"],"recId":"265784670","disp":"Aspirin plus Rivaroxaban versus Rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome the multicenter, multinational, randomized, open-label ARIVA trialCirculation","title":[{"title_sort":"Circulation","subtitle":"an official journal of the American Heart Association","title":"Circulation"}]}],"id":{"eki":["1949769887"],"doi":["10.1161/CIRCULATIONAHA.124.073050"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"28 January 2025"}],"title":[{"title":"Aspirin plus Rivaroxaban versus Rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome","title_sort":"Aspirin plus Rivaroxaban versus Rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome","subtitle":"the multicenter, multinational, randomized, open-label ARIVA trial"}],"recId":"1949769887","type":{"bibl":"article-newspaper","media":"Online-Ressource"},"language":["eng"],"name":{"displayForm":["Stefano Barco, MD, Houman Jalaie, MD, Tim Sebastian, MD, Simon Wolf, MMed, Riccardo M. Fumagalli, MD, Michael Lichtenberg, MD, Thomas Zeller, MD, Christian Erbel, MD, Oliver Schlager, MD, and Nils Kucher, MD"]}} | ||
| SRT | |a BARCOSTEFAASPIRINPLU2820 | ||